211 related articles for article (PubMed ID: 11687017)
41. Chlorambucil for patients with primary biliary cirrhosis.
Li WX; Yan X; Shi CR; Zhang AP
Cochrane Database Syst Rev; 2012 Sep; (9):CD008714. PubMed ID: 22972125
[TBL] [Abstract][Full Text] [Related]
42. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis.
Akriviadis EA; Steindel H; Pinto PC; Fong TL; Kanel G; Reynolds TB; Gupta S
Gastroenterology; 1990 Sep; 99(3):811-8. PubMed ID: 2199290
[TBL] [Abstract][Full Text] [Related]
43. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Mastropasqua E; Orando S; Orlando R
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD005165. PubMed ID: 17253543
[TBL] [Abstract][Full Text] [Related]
44. Use of colchicine and steroids in the treatment of alcoholic liver disease.
Galambos JT; Riepe SP
Recent Dev Alcohol; 1984; 2():181-94. PubMed ID: 6374780
[TBL] [Abstract][Full Text] [Related]
45. Colchicine in primary biliary cirrhosis.
Warnes TW
Aliment Pharmacol Ther; 1991 Aug; 5(4):321-9. PubMed ID: 1777543
[TBL] [Abstract][Full Text] [Related]
46. A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis.
Wang YJ; Lee SD; Hsieh MC; Lin HC; Lee FY; Tsay SH; Tsai YT; Hu OY; King ML; Lo KJ
J Hepatol; 1994 Nov; 21(5):872-7. PubMed ID: 7890905
[TBL] [Abstract][Full Text] [Related]
47. Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial.
Madsen BS; Trebicka J; Thiele M; Israelsen M; Arumugan M; Havelund T; Krag A
Trials; 2018 Feb; 19(1):143. PubMed ID: 29482588
[TBL] [Abstract][Full Text] [Related]
48. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J
J Hepatol; 1999 Jun; 30(6):1081-9. PubMed ID: 10406187
[TBL] [Abstract][Full Text] [Related]
49. Colchicine reduces procollagen III and increases pseudocholinesterase in chronic liver disease.
Muntoni S; Rojkind M; Muntoni S
World J Gastroenterol; 2010 Jun; 16(23):2889-94. PubMed ID: 20556834
[TBL] [Abstract][Full Text] [Related]
50. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.
Parés A; Planas R; Torres M; Caballería J; Viver JM; Acero D; Panés J; Rigau J; Santos J; Rodés J
J Hepatol; 1998 Apr; 28(4):615-21. PubMed ID: 9566830
[TBL] [Abstract][Full Text] [Related]
51. Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver.
Ferenci P; Dragosics B; Dittrich H; Frank H; Benda L; Lochs H; Meryn S; Base W; Schneider B
J Hepatol; 1989 Jul; 9(1):105-13. PubMed ID: 2671116
[TBL] [Abstract][Full Text] [Related]
52. Underreporting of alcohol-related mortality from cirrhosis is declining in Sweden and Denmark.
Prytz H; Anderson H
Scand J Gastroenterol; 1988 Nov; 23(9):1035-43. PubMed ID: 3247585
[TBL] [Abstract][Full Text] [Related]
53. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments.
Lieber CS
Curr Gastroenterol Rep; 2004 Feb; 6(1):60-5. PubMed ID: 14720455
[TBL] [Abstract][Full Text] [Related]
54. Treatment of advanced alcoholic liver disease.
Bird GL; Williams R
Alcohol Alcohol; 1990; 25(2-3):197-206. PubMed ID: 2198035
[TBL] [Abstract][Full Text] [Related]
55. Anti-inflammatory and immunosuppressive treatment of alcoholic liver disease.
Juhl E; Christensen E
Acta Med Scand Suppl; 1985; 703():195-9. PubMed ID: 3867241
[No Abstract] [Full Text] [Related]
56. A prospective randomized trial of colchicine in prevention of liver cirrhosis in chronic hepatitis B patients.
Lin DY; Sheen IS; Chu CM; Liaw YF
Aliment Pharmacol Ther; 1996 Dec; 10(6):961-6. PubMed ID: 8971295
[TBL] [Abstract][Full Text] [Related]
57. Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis.
Ren A; He W; Rao J; Ye D; Cheng P; Jian Q; Fu Z; Zhang X; Deng R; Gao Y; Ma Y
Front Immunol; 2023; 14():1034356. PubMed ID: 36845083
[TBL] [Abstract][Full Text] [Related]
58. Colchicine, serum albumin, and alkaline phosphatase.
Kershenobich D; Uribe M; Suarez GI; Tamayo RP; Rojkind M
Ann Intern Med; 1978 Jul; 89(1):144. PubMed ID: 352218
[No Abstract] [Full Text] [Related]
59. Medical treatment for alcoholic liver disease.
Ramond MJ; Rueff B; Benhamou JP
Baillieres Clin Gastroenterol; 1993 Sep; 7(3):697-716. PubMed ID: 8219407
[TBL] [Abstract][Full Text] [Related]
60. Efficacy and Safety of Emricasan in Liver Cirrhosis and/or Fibrosis.
Mu LY; Li SQ; Tang LX; Li R
Clinics (Sao Paulo); 2021; 76():e2409. PubMed ID: 34133478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
